GEN Exclusives

When Protein Characterization Is Used to Monitor Elusive Proteoforms in Sophisticated Biological Samples, It Should Be Seen in Start-To-Finish Terms

Modifications to Histones Affect Gene Expression and Cell Fate Decisions

Predictions for 2017

Old Becomes Fresh Again

GEN Podcasts

The Sounds of Science podcast is brought to you by GEN. Listen as members of the editorial team—Editor-in-Chief John Sterling, Technical Editor Jeff Buguliskis, and Senior News Editor Alex Philippidis—showcase innovative research, fresh initiatives, and significant policy by interviewing thought-leaders, eminent life-science researchers, and company leaders. These brief, but informative podcasts will keep you up-to-date with the latest and most significant life science advances.

Fresh Drug Delivery Materials May Help Patient Compliance with Meds

Researchers at MIT and Brigham and Women’s Hospital create triggerable harsh hydrogels. Hydrogels may last in belly for lengthy periods of time.

Looking at the CAR-T Landscape As Very first Approval Nears

Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the very first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data.

SARS and MERS Inhibited by Ebola Drug

A research team from Vanderbilt University, University of North Carolina, and Gilead Sciences has just released fresh findings in Science Translational Medicine that a fresh antiviral drug candidate inhibits a broad range of coronaviruses, including SARS and MERS.

Bioengineers Use Quantum Dots to Help Develop Fresh Therapies for Numerous Sclerosis

Team believes a rational therapeutic design treatment will permit scientists to convert how the disease is tackled. Quantum dot technology also should be applicable to other autoimmune diseases as well.

Soft Tissue Synthetic Retina Created

A synthetic, soft tissue retina developed by an Oxford University doctoral chemistry student could suggest fresh hope for visually impaired people.

FDA’s Fresh Commissioner Hits the Ground Running

Sara Radcliffe, President and CEO of the California Life Sciences Association, discusses where Scott Gottlieb, M.D., is most likely to influence biopharma, and what the industry hopes he will accomplish as the FDA’s fresh commissioner.

Fresh Zika Test Shines LAMP in the Dark

A fresh test not only rapidly and inexpensively detects Zika virus in mosquitoes and human bodily fluids, but can also distinguish inbetween African and Asian strains.

Inflammation-Sensing Gut Bacteria Brought to You by Synthetic Biology

Fresh research may eventually lead to orally ingestible bacteria for monitoring gut health and disease—with the ultimate aim being the development of a home inflammation test.

Standing Up Against NIH Budget Cuts

Mary Woolley, President of Research!America, which advocates for medical and health research funding, talks about how her group and other advocates plan to fight back against President Donald Trump’s one-two punch to NIH funding. Researchers will be key to those efforts, she says.

Is Maple Syrup the Response to Antibiotic Resistance?

McGill University researchers may have found a natural way to cut down on antibiotic use without sacrificing health.

Sensitive Genotypes and their Influence on Economic Success

A latest investigate suggest that children with sensitive genotypes who come from low-income homes will be less financially successful than their same hook-up sibling without those genotypes. But children with those same genotypes from a high-income home would actually fare better economically as youthful adults than their brother or sister.

Cancer Immunotherapy: CAR T as ‘Car Race’

Brad Loncar, CEO of Loncar Investments, weighs in on latest developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”?

Cannibalism: A Biological and Evolutionary Perspective

Scientists have long written off cannibalism as a strange phenomenon with little biological significance. However, the true nature of cannibalism—the role it plays in evolution as well as human history—is even more intriguing (and more normal) than the misconceptions we’ve come to accept as fact.

Seeking Youthful Scientists for Research in Space

Nicole M. Nichols, Ph.D., group leader for DNA amplification development at Fresh England Biolabs, discusses the third national Genes in Space competition. The winner will have his or her experiment carried out aboard the International Space Station.

Sorting Out the CRISPR Patent Case

Bill Warren, fucking partner with the law rock-hard Eversheds Sutherland and chair of its biotechnology and life sciences team, discusses the ruling by a three-judge panel of the Patent Trial and Appeal Board siding with the Broad Institute of MIT and Harvard in the bitter legal battle over who invented CRISPR (clustered regularly interspaced brief palindromic repeats) gene-editing technology.

“Sexual Attraction” Neurons in the Brain Discovered

Finding in female mice may also be relevant to certain human psychiatric disorders.

Best Practices for Closing the Gender Gap

Jodie Morrison, CEO and President of Tokai Pharmaceuticals, is one of almost two hundred biopharma leaders who recently signed an open letter endorsing a Top Ten of best practices for advancing gender diversity, from the boardroom to the C-suite to the lab.

When the Pressure Is High the Dementia Is Low

Findings from a fresh investigate suggest that the onset of high blood pressure later in life is associated with lower dementia risk after age 90. Listen now for more details!

Taking on the Multi-Drug-Resistant Bacteria Challenge

Entasis Therapeutics is working on novel therapies for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients.

What Trump Will Mean for Biomedical Research

Benjamin Corb, public affairs director for the American Society for Biochemistry and Molecular Biology (ASBMB), discusses what the biomedical research community can expect from the incoming administration of Donald J. Trump.

Related movie: